OvuGel

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Triptorelin acetate

Available from:

Vetoquinol

ATC code:

QH01CA97

INN (International Name):

Triptorelin

Therapeutic group:

Pigs (sows for reproduction)

Therapeutic area:

Ormoni u analogi pitwitarji u ipotalamiċi

Therapeutic indications:

For the synchronisation of ovulation in weaned sows to enable a single fixed-time artificial insemination.

Authorization status:

Awtorizzat

Authorization date:

2020-11-10

Patient Information leaflet

                                15
B. FULJETT TA’ TAGĦRIF
16
FULJETT TA’ TAGĦRIF GĦAL:
OVUGEL 0.1 MG/ML ĠEL VAĠINALI GĦALL-MAJJALI NISA
GĦAR-RIPRODUZZJONI
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq u l-manifattur
responsabbli għall-ħrug tal-lott:
Vetoquinol S.A.
Magny-Vernois
70200 LURE
Franza
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
OvuGel 0.1 mg/mL ġel vaġinali għall-majjali nisa
għar-riproduzzjoni
triptorelin
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull mL fih:
Sustanza attiva:
Triptorelin (bħala triptorelin acetate)
0.1 mg
Ingredjenti oħra:
Sodium methyl parahydroxybenzoate
0.9 mg
Sodium propyl parahydroxybenzoate
0.1 mg
Ġel irqiq ċar għal kemmxejn imċajpar.
4.
INDIKAZZJONI(JIET)
Għas-sinkronizzazzjoni tal-ovulazzjoni f’majjali nisa miftuma biex
tkun possibbli inseminazzjoni
artifiċjali waħda f’ħin stabbilit.
5.
KONTRAINDIKAZZJONIJIET
Tużax f’każ ta’ sensittività għas-sustanza attiva jew
ingredjenti oħra.
Tużax waqt it-tqala u/jew it-treddigħ.
Tużax f’majjali nisa b’anormalitajiet ovvji fl-apparat
riproduttiv.
6.
EFFETTI MHUX MIXTIEQA
M’hemm xejn magħruf.
Jekk tinnota xi effetti sekondarji, anke dawk mhux imsemmija f’dan
il-fuljett, jew taħseb li l-mediċina
ma ħadmitx, jekk jogħġbok informa lit-tabib veterinarju tiegħek.
17
7.
SPEĊI GĦAL XIEX HUWA INDIKAT IL-PRODOTT
Ħnieżer (majjali nisa għar-riproduzzjoni)
8.
DOŻA GĦAL KULL SPEĊI, MOD(I) U METODU TA’ AMMINISTRAZZJONI
Kull majjala għandha tirċievi doża waħda ta’ 2 mL (ekwivalenti
għal 0.2 mg) tal-prodott ġol-vagina
bl-użu ta’ siringa li timtela waħedha disponibbli kummerċjalment
b’labra li tiġbed, iddisinjata biex
tagħti dożi preċiżi ta’ 2 mL u li fuqha jista’ jiġi mdaħħal
tubu għal infużjoni ġol-vaġina.
OvuGel għandu jiġi amministrat ġol-vaġina madwar 96 siegħa wara

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
OvuGel 0.1 mg/mL ġel vaġinali għall-majjali nisa
għar-riproduzzjoni
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull mL fih:
Sustanza attiva:
Triptorelin (bħala triptorelin acetate)
0.1 mg
Ingredjenti oħra:
Sodium methyl parahydroxybenzoate
0.9 mg
Sodium propyl parahydroxybenzoate
0.1 mg
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Ġel vaġinali.
Ġel irqiq ċar għal kemmxejn imċajpar.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Ħanżir (majjala għar-riproduzzjoni)
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT
Għas-sinkronizzazzjoni tal-ovulazzjoni f’majjali nisa miftuma biex
tkun possibbli inseminazzjoni
artifiċjali waħda f’ħin stabbilit.
4.3
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ sensittività għall-ingredjent attiv jew
ingredjenti oħra.
Tużax waqt it-tqala u/jew it-treddigħ.
Tużax f’majjali nisa b’anormalitajiet ovvji fl-apparat
riproduttiv.
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA HU INDIKAT
IL-PRODOTT
L-effikaċja ta’ OvuGel ma ntwerietx fi ħnieżer nisa qabel
ir-refgħa (
_gilts_
, majjali nisa nulliparużi), u l-
użu tal-prodott mediċinali veterinarju għalhekk mhux rakkomandat
f’dawn l-annimali.
Ir-rispons tal-majjali nisa għall-protokolli ta’ sinkronizzazzjoni
jista’ jkun influwenzat mill-istat
fiżjoloġiku fil-ħin tat-trattament. Ir-rispons għat-trattament
mhuwiex uniformi la fost il-merħliet u
lanqas bejn individwi fi ħdan il-merħliet.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
Prekawzjonijiet speċjali għall-użu fl-annimali
Il-prodott m’għandux jintuża f’majjali nisa b’anormalitajiet
fl-apparat riproduttiv, b’infertilità jew
disturbi ġenerali tas-saħħa.
3
Twettaq studju dwar is-sigurtà riproduttiva f’majjali nisa wara
l-amministrazzjoni ta’ doża 3 darbiet
dik rakkomandata ta’ Ovugel, u d
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-05-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-05-2021
Public Assessment Report Public Assessment Report Bulgarian 12-10-2023
Patient Information leaflet Patient Information leaflet Spanish 07-05-2021
Public Assessment Report Public Assessment Report Spanish 12-10-2023
Patient Information leaflet Patient Information leaflet Czech 07-05-2021
Public Assessment Report Public Assessment Report Czech 12-10-2023
Patient Information leaflet Patient Information leaflet Danish 07-05-2021
Public Assessment Report Public Assessment Report Danish 12-10-2023
Patient Information leaflet Patient Information leaflet German 07-05-2021
Public Assessment Report Public Assessment Report German 12-10-2023
Patient Information leaflet Patient Information leaflet Estonian 07-05-2021
Public Assessment Report Public Assessment Report Estonian 12-10-2023
Patient Information leaflet Patient Information leaflet Greek 07-05-2021
Public Assessment Report Public Assessment Report Greek 12-10-2023
Patient Information leaflet Patient Information leaflet English 07-05-2021
Patient Information leaflet Patient Information leaflet French 07-05-2021
Public Assessment Report Public Assessment Report French 12-10-2023
Patient Information leaflet Patient Information leaflet Italian 07-05-2021
Public Assessment Report Public Assessment Report Italian 12-10-2023
Patient Information leaflet Patient Information leaflet Latvian 07-05-2021
Public Assessment Report Public Assessment Report Latvian 12-10-2023
Patient Information leaflet Patient Information leaflet Lithuanian 07-05-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-05-2021
Public Assessment Report Public Assessment Report Lithuanian 12-10-2023
Patient Information leaflet Patient Information leaflet Hungarian 07-05-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-05-2021
Public Assessment Report Public Assessment Report Hungarian 12-10-2023
Patient Information leaflet Patient Information leaflet Dutch 07-05-2021
Public Assessment Report Public Assessment Report Dutch 12-10-2023
Patient Information leaflet Patient Information leaflet Polish 07-05-2021
Public Assessment Report Public Assessment Report Polish 12-10-2023
Patient Information leaflet Patient Information leaflet Portuguese 07-05-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-05-2021
Public Assessment Report Public Assessment Report Portuguese 12-10-2023
Patient Information leaflet Patient Information leaflet Romanian 07-05-2021
Public Assessment Report Public Assessment Report Romanian 12-10-2023
Patient Information leaflet Patient Information leaflet Slovak 07-05-2021
Public Assessment Report Public Assessment Report Slovak 12-10-2023
Patient Information leaflet Patient Information leaflet Slovenian 07-05-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 07-05-2021
Public Assessment Report Public Assessment Report Slovenian 12-10-2023
Patient Information leaflet Patient Information leaflet Finnish 07-05-2021
Public Assessment Report Public Assessment Report Finnish 12-10-2023
Patient Information leaflet Patient Information leaflet Swedish 07-05-2021
Public Assessment Report Public Assessment Report Swedish 12-10-2023
Patient Information leaflet Patient Information leaflet Norwegian 07-05-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-05-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-05-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-05-2021
Patient Information leaflet Patient Information leaflet Croatian 07-05-2021
Public Assessment Report Public Assessment Report Croatian 12-10-2023

Search alerts related to this product

View documents history